High-risk Smoldering Multiple Myeloma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2020-01-27
Clinical Trial Update: A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma [Phase 2]
Phase 2 trial investigating siltuximab for high-risk smoldering multiple myeloma has completed with results posted.